AlphaCrest Capital Management LLC lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating) by 42.8% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 3,302 shares of the company’s stock after buying an additional 990 shares during the quarter. AlphaCrest Capital Management LLC’s holdings in IDEXX Laboratories were worth $1,806,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also modified their holdings of the business. Norges Bank bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $494,883,000. American Century Companies Inc. grew its position in shares of IDEXX Laboratories by 32.1% during the first quarter. American Century Companies Inc. now owns 1,423,600 shares of the company’s stock worth $778,795,000 after acquiring an additional 346,118 shares during the last quarter. BlackRock Inc. grew its position in IDEXX Laboratories by 3.4% in the 4th quarter. BlackRock Inc. now owns 8,990,586 shares of the company’s stock worth $5,919,940,000 after purchasing an additional 296,552 shares during the last quarter. UMB Bank N A MO increased its position in IDEXX Laboratories by 4,072.8% in the 4th quarter. UMB Bank N A MO now owns 287,464 shares of the company’s stock valued at $189,284,000 after acquiring an additional 280,575 shares during the period. Finally, Alliancebernstein L.P. raised its stake in IDEXX Laboratories by 18.9% during the 4th quarter. Alliancebernstein L.P. now owns 1,596,308 shares of the company’s stock valued at $1,051,105,000 after acquiring an additional 254,033 shares in the last quarter. 88.45% of the stock is owned by institutional investors and hedge funds.
IDEXX Laboratories Stock Performance
Shares of IDXX opened at $348.84 on Wednesday. IDEXX Laboratories, Inc. has a one year low of $318.50 and a one year high of $695.18. The company has a 50-day moving average of $375.30 and a two-hundred day moving average of $427.07. The company has a debt-to-equity ratio of 1.68, a current ratio of 0.89 and a quick ratio of 0.61. The stock has a market cap of $29.04 billion, a price-to-earnings ratio of 45.01, a PEG ratio of 4.65 and a beta of 1.14.
Analysts Set New Price Targets
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.
- Get a free copy of the StockNews.com research report on IDEXX Laboratories (IDXX)
- How the Pandemic Forced F5 to Flex its Software Side
- Shock Absorbers: 3 Low Volatility Dividend Stocks for Bumpy Times
- The Retail Sector: Winners And Losers From Q2 Earnings
- Can Targa Continue Rallying To Meet Its Price Target?
- Is Unity Software Ready To Rally After Rejecting AppLovin Offer?
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.